Last update July 25, 2022
Very Low Risk
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Doxazosin Mesylate in other languages or writings:
Doxazosin Mesylate belongs to these groups or families:
Main tradenames from several countries containing Doxazosin Mesylate in its composition:
|Oral Bioavail.||65 - 68||%|
|Protein Binding||98 - 99||%|
|Tmax||2 (retard: 8 - 9)||hours|
|T½||19 - 22||hours|
|Theoretical Dose||0.0004 - 0.0006||mg/Kg/d|
|Relative Dose||0.6 - 0.9||%|
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is an alpha-1-adrenergic blocking agent that is used for treatment of arterial hypertension and of obstructive symptoms resulting from benign prostatic hypertrophy. Oral administration once a day.
Its pharmacokinetic data, -moderately elevated molecular weight, high percentage of plasma protein binding and high volume of distribution (Pfizer 2017, Kirsten 1998, Elliot 1987)-, probably explain the negligible excretion observed in milk. (Pfizer 2017, Versmissen 2016, Jensen 2013 y 2014)
Until more extensive published data about this drug regarding breastfeeding are available a safer alternative drug may be used (Anderson 2018, Schaefer 2007 p685), especially during the neonatal period and/or in case of premature infants.